Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 4/2007

01-04-2007 | Article

Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes

Authors: S. M. Gold, I. Dziobek, V. Sweat, A. Tirsi, K. Rogers, H. Bruehl, W. Tsui, S. Richardson, E. Javier, A. Convit

Published in: Diabetologia | Issue 4/2007

Login to get access

Abstract

Aims/hypothesis

There is evidence that type 2 diabetes mellitus is associated with cognitive impairment. Most studies investigating this association have evaluated elderly individuals, after many years of diabetes, who generally have poor glycaemic control and significant vascular disease. The aim of the current study was to investigate the early cognitive consequences and associated brain correlates of type 2 diabetes.

Materials and methods

With regard to cognition and brain measures, we compared 23 age-, sex- and education-matched control subjects with 23 mostly middle-aged individuals with relatively well-controlled diabetes of less than 10 years from the time of diagnosis.

Results

We found deficits in hippocampal-based memory performance and preservation of other cognitive domains. Relative to control subjects, individuals with diabetes had reductions in brain volumes that were restricted to the hippocampus. There was an inverse relationship between glycaemic control and hippocampal volume; in multivariate regression analysis, HbA1c was the only significant predictor of hippocampal volume, accounting for 33% of the observed variance. Other variables commonly associated with type 2 diabetes, such as elevated BMI, hypertension or dyslipidaemia, did not independently contribute to the variance in hippocampal volume.

Conclusions/interpretation

These results suggest that the medial temporal lobe may be the first brain site affected by type 2 diabetes and that individuals in poorer metabolic control may be affected to a greater extent.
Literature
1.
Cowie CC, Rust KF, Byrd-Holt DD et al (2006) Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999–2002. Diabetes Care 29:1263–1268PubMedCrossRef
2.
Strachan M, Deary I, Ewing F, Frier B (2002) Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care 20:438–445
3.
Biessels G-J, ter Braak E, Erkelens D, Hijman R (2001) Cognitive function in patients with type 2 diabetes mellitus. Neurosci Res Commun 28:11–22CrossRef
4.
Manschot SM, Brands AMA, van der Grond J et al (2006) Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes 55:1106–1113PubMedCrossRef
5.
Ryan CM, Geckle MO (2000) Circumscribed cognitive dysfunction in middle-aged adults with type 2 diabetes. Diabetes Care 23:1486–1493PubMed
6.
Araki Y, Nomura M, Tanaka H et al (1994) MRI of the brain in diabetes mellitus. Neuroradiology 36:101–103PubMedCrossRef
7.
den Heijer T, Vermeer SE, van Dijk EJ et al (2003) Type 2 diabetes and atrophy of the medial temporal lobe structures. Diabetologia 46:1604–1610CrossRef
8.
Korf ESC, White LR, Scheltens P, Launer LJ (2006) Brain aging in very old men with type 2 diabetes: the Honolulu-Asia aging study. Diabetes Care 29:2268–2274PubMedCrossRef
9.
Kumari M, Brunner E, Fuhrer R (2000) Minireview: mechanisms by which the metabolic syndrome and diabetes impair memory. J Gerontol 55A:B228–B232
10.
Reaven GM, Thompson LW, Nahum D, Haskins E (1990) Relationship between hyperglycemia and cognitive function in older NIDDM patients. Diabetes Care 13:16–21PubMed
11.
Schneider D, Sobel B (1997) Determinants of coronary vascular disease in patients with type II diabetes mellitus and their therapeutic implications. Clin Cardiol 20:433–440PubMed
12.
13.
Taskinen M, Smith U (1998) Lipid disorders in NIDDM: implications for treatment. J Intern Med 244:361–370PubMedCrossRef
14.
Jellinger P (2000) The American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of dyslipidemia and prevention of atherogenesis. Endocr Pract 6:162–213PubMed
15.
Cournot M, Marquie JC, Ansiau D et al (2006) Relation between body mass index and cognitive function in healthy middle-aged men and women. Neurology 67:1208–1214PubMedCrossRef
16.
Ward MA, Carlsson CM, Trivedi MA, Sager MA, Johnson SC (2005) The effect of body mass index on global brain volume in middle-aged adults: a cross sectional study. BMC Neurol 5:23PubMedCrossRef
17.
Gold SM, Dziobek I, Rogers K, Bayoumy A, McHugh PF, Convit A (2005) Hypertension and hypothalamo–pituitary–adrenal axis hyperactivity affect frontal lobe integrity. J Clin Endocrinol Metab 90:3262–3267PubMedCrossRef
18.
Papademetriou V (2005) Hypertension and cognitive function. Blood pressure regulation and cognitive function: a review of the literature. Geriatrics 60:20–22, 24PubMed
19.
Meneilly GS, Cheung E, Tessier D, Yakura C, Tuokko H (1993) The effect of improved glycemic control on cognitive functions in the elderly patient with diabetes. J Gerontol 48:M117–M121PubMed
20.
Gradman TJ, Laws A, Thompson LW, Reaven GM (1993) Verbal learning and/or memory improves with glycemic control in older subjects with non-insulin-dependent diabetes mellitus. J Am Geriatr Soc 41:1305–1312PubMed
21.
Vanhanen M, Koivisto K, Karjalainen L et al (1997) Risk for non-insulin-dependent diabetes in the normoglycaemic elderly is associated with impaired cognitive function. NeuroReport 8:1527–1530PubMedCrossRef
22.
Convit A, Wolf OT, Tarshish C, de Leon MJ (2003) Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proc Natl Acad Sci U.S.A. 100:2019–2022PubMedCrossRef
23.
Kalmijn S, Feskens EJM, Launer LJ, Stijnen T, Kromhout D (1995) Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men. Diabetologia 38:1096–1102PubMed
24.
Delis DC, Kramer JH, Kaplan E, Ober BA (1987) California verbal learning test—research edition. The Psychological Corporation, New York
25.
Wechsler D (1987) Wechsler memory scale–revised. Psychological Corporation/Harcourt Brace Javanovich, San Antonio
26.
Gilbert JG, Levee RF, Catalano FL (1968) A preliminary report on a new memory scale. Percept Mot Skills 27:277–278
27.
Golden CJ (1978) Stroop color and word test: a manual for clinical and experimental uses. Stoeiting Company, Wood Dale
28.
Zachary RA (1940) Shipley Institute of living scale—revised. Western Psychological Services, Los Angeles
29.
Zachary RA, Paulson MJ, Gorsuch RL (1985) Estimating WAIS IQ from the Shipley Institute of Living Scale using continuously adjusted age norms. J Clin Psychol 41:820–831PubMed
30.
Marcus S, Robins LN, Bucholz K (1988) Quick diagnostic interview schedule III-R. Version 1.0. Washington University School of Medicine, St Louis
31.
32.
Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A (1980) Pathological verification of ischemia score in differentiation of dementias. Ann Neurol 7:486–488PubMedCrossRef
33.
Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA (1987) MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. Am J Roentgenol 149:351–356
34.
Scheltens P, Barkhof F, Leys D et al (1993) A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 114:7–12PubMedCrossRef
35.
Convit A, de Leon MJ, Tarshish C et al (1997) Specific hippocampal volume reductions in individuals at risk for Alzheimer’s disease. Neurobiol Aging 18:131–138PubMedCrossRef
36.
Convit A, Wolf OT, de Leon MJ et al (2001) Volumetric analysis of the pre-frontal regions: findings in aging and schizophrenia. Psychiatry Res 107:61–73PubMed
37.
Convit A, McHugh PR, Wolf OT et al (1999) MRI volume of the amygdala: a reliable method allowing separation from the hippocampal formation. Psychiatry Res 90:113–123PubMed
38.
Bobinski M, de Leon MJ, Wegiel J et al (2000) The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer’s disease. Neurosci 95:721–725CrossRef
39.
Jack CRJ, Bentley MD, Twomey CK, Zinsmeister AR (1990) MR imaging-based volume measurements of the hippocampal formation and anterior temporal lobe: validation studies. Radiology 176:205–209PubMed
40.
Van Petten C (2004) Relationship between hippocampal volume and memory ability in healthy individuals across the lifespan: review and meta-analysis. Neuropsychologia 42:1394–1413PubMedCrossRef
41.
Good CD, Johnsrude IS, Ashburner J, Henson RNA, Friston KJ, Frackowiak RSJ (2001) A voxel-based morphometric study of ageing in 465 normal adult human brains. NeuroImage 14:21–36PubMedCrossRef
42.
Expert Panel (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRef
43.
Akisaki T, Sakurai T, Takata T et al (2006) Cognitive dysfunction associates with white matter hyperintensities and subcortical atrophy on magnetic resonance imaging of the elderly diabetes mellitus Japanese elderly diabetes intervention trial (J-EDIT). Diabetes Metab Res Rev 22:376–384PubMedCrossRef
44.
45.
Convit A (2005) Links between cognitive impairment in insulin resistance: an explanatory model. Neurobiol Aging 26:31–35PubMedCrossRef
46.
Lobnig BM, Kroemeke O, Optenhostert-Porst C, Wolf OT (2006) Hippocampal volume and cognitive performance in long-standing type 1 diabetic patients without macrovascular complications. Diabet Med 23:32–39PubMedCrossRef
47.
Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820PubMedCrossRef
48.
McNay EC, Fries TM, Gold PE (2000) Decreases in rat extracellular hippocampal glucose concentration associated with cognitive demand during a spatial task. Proc Natl Acad Sci 97:2881–2885PubMedCrossRef
Metadata
Title
Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes
Authors
S. M. Gold
I. Dziobek
V. Sweat
A. Tirsi
K. Rogers
H. Bruehl
W. Tsui
S. Richardson
E. Javier
A. Convit
Publication date
01-04-2007
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 4/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-007-0602-7

Other articles of this Issue 4/2007

Diabetologia 4/2007 Go to the issue

Article

Predictive impact of elevated serum level of IL-18 for early renal dysfunction in type 2 diabetes: an observational follow-up study

Article

Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes

Article

Prevalence and incidence rate of diabetes mellitus in a Swedish community during 30 years of follow-up

Short Communication

A genetic variation of the transcription factor 7-like 2 gene is associated with risk of type 2 diabetes in the Japanese population

Short Communication

Deletion of the gene encoding the islet-specific glucose-6-phosphatase catalytic subunit-related protein autoantigen results in a mild metabolic phenotype

Article

Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS)
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits